Table 2 Summary of vaccine trials using hookworm excretory/secretory products

Ac-ASP-1

42.0

Alum-precipitated RP

IP

Larval migration inhibition

A. caninum

Animal trial

[150]

Ac-ASP-2

24.2

RP/Glaxo SmithKline adjuvant

IM

Larval migration inhibition

A. caninum

Animal trial

[26]

Ace-ASP-2

24.0

RP/Quil A

IM

Larval migration inhibition

A. ceylanicum

Animal trial

[19]

Na-ASP-2

21.3

RP/Alhydrogel

IM

Larval migration inhibition

N. americanus

Phase 1 clinical trial

[28]

Ac-MTP-1

61.0

RP/Glaxo SmithKline adjuvant

IM

Larval migration inhibition

A. caninum

Animal trial

[155]

Ac-APR-1

~ 50.0

RP/Glaxo SmithKline adjuvant

IM

Reduction of anemia, worm burden, and egg count

A. caninum

Animal trial

[156]

RP/Alhydrogel

SC

Worm burden reduction

N. americanus

Animal trial

[28]

Mutant Na-APR-1

na

Mutant protein /Alhydrogel

IM

Reduction of anemia, weight loss, and egg counts

A. caninum

Animal trial

[158]

Ac-GST-1

30.0

RP/Glaxo SmithKline adjuvant

IM

Worm burden and egg count reduction

A. caninum

Animal trial

[93]

RP/Alhydrogel

SC

Worm burden and egg count reduction

N. americanus

Animal trial

[28]

Na-GST-1

24.0

RP/Alhydrogel

IM

Worm burden reduction

N. americanus

Phase 1 clinical trial

[90, 95]

Ace-KI-1

7.9

RP/Freund’s adjuvant

SC

Malnutrition and growth delay prevention

A. ceylanicum

Animal trial

[79]

Calreticulin

56.0

RP in phosphate buffer saline

IP

Worm burden reduction in lungs

N. americanus

Animal trial

[161]

Ace-ES-2

11.6

RP in 1.5 M NaCl

PO

Decreasing anemia and improving the recovery rate

A. ceylanicum

Animal trial

[125]

Ace-FAR-1

20.0

RP/cholera toxin

PO

Worm burden reduction

A. ceylanicum

Animal trial

[144]